Home Tags Triple negative breast cancer

Tag: triple negative breast cancer

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Sacituzumab Govitecan Achieves 29 Percent ORR in Advanced Urothelial...

Interim data from a 100-patient cohort of cisplatin-eligible patients participating in the TROPHY-U-01, an international, multi-center, open-label, phase II study, in patients with metastatic...

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

Indatuximab Ravtansine Shows Good Tolerability and Signs of Efficacy in Phase...

Results for Phase I/IIa study confirms that indatuximab ravtansine, also known as BT-062, an antibody-drug conjugate being developed by Biotets, offers good tolerability and...

Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...

Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...

Sacituzumab Govitecan Receives Breakthrough Therapy Designation for Triple-negative Breast Cancer

The investigational antibody-drug conjugate, sacituzumab govitecan, also know as IMMU-132 (Immunomedics), has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA)...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...